FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Lenting

Research Profile

Chemicals & Drugs

Phenomena

Protein Binding

Living Beings

Concepts & Ideas

Disorders

von Willebrand's Diseases

Procedures

Surface Plasmon Resonance

Anatomy

Co-author Network

Publications

TOP 3
Jenny McIntosh; John H McVey; Federico Mingozzi; Christopher L Morton; Maria Cancio; Olivier D Christophe; Andrew M Davidoff; Paolo Fagone; John T Gray; Katherine A High; Doyoung Lee; Peter J Lenting; Catherine Y C Ng; Arthur W Nienhuis; Nishil Patel; Samira Rabbanian; Deepak Raj; Cecilia Rosales; Edward G D Tuddenham; Simon Waddington; Junfang Zhou; Shang-Zhen Zhou; Amit C Nathwani
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.
Paulette Legendre; Peter J Lenting; Ana-Maria Navarrete; Julie Rayes; Catherine Ternisien; Agnès Veyradier; Pierre Boisseau; Claudine Caron; Caterina Casari; Cécile V Denis; Edith Fressinaud; Jenny Goudemand; Olivier D Christophe
Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein.
Peter J Lenting; C Casari; Olivier D Christophe; Cécile V Denis
von Willebrand factor: the old, the new and the unknown.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Lenting (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jenny McIntosh; John H McVey; Federico Mingozzi; Christopher L Morton; Maria Cancio; Olivier D Christophe; Andrew M Davidoff; Paolo Fagone; John T Gray; Katherine A High; Doyoung Lee; Peter J Lenting; Catherine Y C Ng; Arthur W Nienhuis; Nishil Patel; Samira Rabbanian; Deepak Raj; Cecilia Rosales; Edward G D Tuddenham; Simon Waddington; Junfang Zhou; Shang-Zhen Zhou; Amit C Nathwani
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.
Blood 2013;121(17):3335-44.
2013: Paulette Legendre; Peter J Lenting; Ana-Maria Navarrete; Julie Rayes; Catherine Ternisien; Agnès Veyradier; Pierre Boisseau; Claudine Caron; Caterina Casari; Cécile V Denis; Edith Fressinaud; Jenny Goudemand; Olivier D Christophe
Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein.
Blood 2013;121(11):2135-43.
2012: Peter J Lenting; C Casari; Olivier D Christophe; Cécile V Denis
von Willebrand factor: the old, the new and the unknown.
Journal of thrombosis and haemostasis : JTH 2012;10(12):2428-37.
2012: Julie N Pegon; Soline Odouard; Caterina Casari; Olivier D Christophe; Cécile V Denis; Mohamad Kurdi; Peter J Lenting
Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5.
Haematologica 2012;97(12):1855-63.
2012: Ana-Maria Navarrete; Caterina Casari; Olivier D Christophe; Jiun-Ruey Hu; Paulette Legendre; Peter J Lenting; Isabelle Marx; Cécile V Denis
A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor.
Blood 2012;120(13):2723-32.
2012: Cécile V Denis; Peter J Lenting
von Willebrand factor: at the crossroads of bleeding and thrombosis.
International journal of hematology 2012;95(4):353-61.
2012: Nathalie Saint-Lu; Soline Odouard; Beatrijs D Oortwijn; Julie N Pegon; Olivier D Christophe; Philip G de Groot; Cécile V Denis; Peter J Lenting
Identification of galectin-1 and galectin-3 as novel partners for von Willebrand factor.
Arteriosclerosis, thrombosis, and vascular biology 2012;32(4):894-901.
2012: Ghasem Rastegarlari; Nathalie Saint-Lu; Bart J van Vlijmen; Ana-Maria Navarrete; Soline Odouard; Julie N Pegon; Caterina Casari; Olivier D Christophe; Cécile V Denis; Paulette Legendre; Peter J Lenting
Macrophage LRP1 contributes to the clearance of von Willebrand factor.
Blood 2012;119(9):2126-34.
2012: Mohamad Kurdi; Peter J Lenting; Ghislaine Cherel; Cécile V Denis; Olivier D Christophe
Coagulation factor X interaction with macrophages through its N-glycans protects it from a rapid clearance.
PloS one 2012;7(9):e45111.
2012: Idinath Badirou; Marijke Bryckaert; Caterina Casari; Olivier D Christophe; Mohamad Kurdi; Paulette Legendre; Peter J Lenting; Julie Rayes; Cécile V Denis
In vivo analysis of the role of O-glycosylations of von Willebrand factor.
PloS one 2012;7(5):e37508.
2011: Peter J Lenting
SHEARiO, fast lane to oxidized VWF.
Blood 2011;118(19):5068-9.
2011: Martine J Hollestelle; Peter J Lenting; C M Loots; J C M Meijers; T Renné; A Squizzato; Berto J Bouma; Philip G de Groot; V E A Gerdes
Decreased active von Willebrand factor level owing to shear stress in aortic stenosis patients.
Journal of thrombosis and haemostasis : JTH 2011;9(5):953-8.
2011: Junmei Chen; William E Hobbs; Jennie Le; Peter J Lenting; Philip G de Groot; José A López
The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma.
Blood 2011;117(13):3680-3.
2011: Martine J Hollestelle; Ka Wai Lai; Peter J Lenting; Tom Sprong; Marcel van Deuren; Philip G de Groot; Niels Bovenschen
Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity.
PloS one 2011;6(9):e24216.
2010: Tessa A M Steevels; Geertje H A Westerlaken; Marloes R Tijssen; Paul J Coffer; Peter J Lenting; Jan-Willem N Akkerman; Linde Meyaard
Co-expression of the collagen receptors leukocyte-associated immunoglobulin-like receptor-1 and glycoprotein VI on a subset of megakaryoblasts.
Haematologica 2010;95(12):2005-12.
2010: I Badirou; M Kurdi; J Rayes; Paulette Legendre; Olivier D Christophe; Peter J Lenting; Cécile V Denis
von Willebrand factor clearance does not involve proteolysis by ADAMTS-13.
Journal of thrombosis and haemostasis : JTH 2010;8(10):2338-40.
2010: Julie Rayes; Martine J Hollestelle; Paulette Legendre; Isabelle Marx; Philip G de Groot; Olivier D Christophe; Peter J Lenting; Cécile V Denis
Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B.
Blood 2010;115(23):4870-7.
2010: M C van Schie; Moniek P M de Maat; Diederik W J Dippel; Philip G de Groot; Peter J Lenting; Frank W G Leebeek; Martine J Hollestelle
von Willebrand factor propeptide and the occurrence of a first ischemic stroke.
Journal of thrombosis and haemostasis : JTH 2010;8(6):1424-6.
2010: Martine J Hollestelle; T Sprong; Niels Bovenschen; Q de Mast; A J van der Ven; L A B Joosten; C Neeleman; Agon Hyseni; Peter J Lenting; Philip G de Groot; M van Deuren
von Willebrand factor activation, granzyme-B and thrombocytopenia in meningococcal disease.
Journal of thrombosis and haemostasis : JTH 2010;8(5):1098-106.
2010: Peter J Lenting; O D Christophe; P Guéguen
The disappearing act of factor VIII.
Haemophilia : the official journal of the World Federation of Hemophilia 2010;16(102):6-15.
2010: Marianne C van Schie; Moniek P M de Maat; Philip G de Groot; Agon Hyseni; Diederik W J Dippel; Peter J Lenting; Frank W G Leebeek; Martine J Hollestelle
Active von Willebrand factor and the risk of stroke.
Atherosclerosis 2010;208(2):322-3.
2010: Peter J Lenting; Geertje H A Westerlaken; Cécile V Denis; Jan Willem Akkerman; Linde Meyaard
Efficient inhibition of collagen-induced platelet activation and adhesion by LAIR-2, a soluble Ig-like receptor family member.
PloS one 2010;5(8):e12174.
2010: Robert H E Friesen; Wouter Koudstaal; Martin H Koldijk; Gerrit Jan Weverling; Just P J Brakenhoff; Peter J Lenting; Koert J Stittelaar; Albert D M E Osterhaus; Ronald Kompier; Jaap Goudsmit
New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets.
PloS one 2010;5(2):e9106.
2009: Sara Zanardelli; Alain C K Chion; Evelyn Groot; Peter J Lenting; Thomas A J McKinnon; Michael A Laffan; Michelle Tseng; David A Lane
A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF.
Blood 2009;114(13):2819-28.
2009: Evelyn Groot; Rob Fijnheer; S A E Sebastian; Ph G de Groot; Peter J Lenting
The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission.
Journal of thrombosis and haemostasis : JTH 2009;7(6):962-9.
2009: Augusto B Federici; Pier M Mannucci; Giancarlo Castaman; Luciano Baronciani; Paolo Bucciarelli; Maria Teresa Canciani; Alessandro Pecci; Peter J Lenting; Philip G de Groot
Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients.
Blood 2009;113(3):526-34.
2009: Kathelijn Fischer; Ronan Pendu; Carina J M van Schooten; Karin van Dijk; Cécile V Denis; H Marijke van den Berg; Peter J Lenting
Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients.
PloS one 2009;4(8):e6745.
2008: Carina J M van Schooten; Shirin Shahbazi; Evelyn Groot; Beatrijs D Oortwijn; H Marijke van den Berg; Cécile V Denis; Peter J Lenting
Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo.
Blood 2008;112(5):1704-12.
2008: Simon F De Meyer; Nele Vandeputte; Inge Pareyn; Inge Petrus; Peter J Lenting; Marinee K L Chuah; Thierry VandenDriessche; Hans Deckmyn; Karen Vanhoorelbeke
Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease.
Arteriosclerosis, thrombosis, and vascular biology 2008;28(9):1621-6.
2008: Isabelle Marx; Olivier D Christophe; Peter J Lenting; Alain Rupin; Marie-Odile Vallez; Tony J Verbeuren; Cécile V Denis
Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa.
Blood 2008;112(3):603-9.
2008: Wenjing Cao; Senthil Kumar Krishnaswamy; Rodney M Camire; Peter J Lenting; X Long Zheng
Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(21):7416-21.
2008: Bert-Jan H van den Born; Niels V van der Hoeven; Evelyn Groot; Peter J Lenting; Joost C M Meijers; Marcel Levi; Gert A van Montfrans
Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension.
Hypertension 2008;51(4):862-6.
2008: Patricia P Spijkers; Cécile V Denis; Anna M Blom; Peter J Lenting
Cellular uptake of C4b-binding protein is mediated by heparan sulfate proteoglycans and CD91/LDL receptor-related protein.
European journal of immunology 2008;38(3):809-17.
2008: Isabelle Marx; Peter J Lenting; Thure Adler; Ronan Pendu; Olivier D Christophe; Cécile V Denis
Correction of bleeding symptoms in von Willebrand factor-deficient mice by liver-expressed von Willebrand factor mutants.
Arteriosclerosis, thrombosis, and vascular biology 2008;28(3):419-24.
2008: Cécile V Denis; Olivier D Christophe; Beatrijs D Oortwijn; Peter J Lenting
Clearance of von Willebrand factor.
Thrombosis and haemostasis 2008;99(2):271-8.
2008: Robert Jan Lebbink; Maaike C W van den Berg; Talitha Eshuis - de Ruiter; Nicolas Raynal; Joel A G van Roon; Peter J Lenting; Boquan Jin; Linde Meyaard
The soluble leukocyte-associated Ig-like receptor (LAIR)-2 antagonizes the collagen/LAIR-1 inhibitory immune interaction.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(3):1662-9.
2008: J Stakiw; M Bowman; Carol Hegadorn; C Pruss; Colleen Notley; Evelyn Groot; Peter J Lenting; Dilys Rapson; David Lillicrap; P James
The effect of exercise on von Willebrand factor and ADAMTS-13 in individuals with type 1 and type 2B von Willebrand disease.
Journal of thrombosis and haemostasis : JTH 2008;6(1):90-6.
2007: Suzanne J A Korporaal; Miranda van Eck; Jelle Adelmeijer; Martin J W IJsseldijk; Ruud Out; Ton Lisman; Peter J Lenting; Theo Van berkel; Jan-Willem N Akkerman
Platelet activation by oxidized low density lipoprotein is mediated by CD36 and scavenger receptor-A.
Arteriosclerosis, thrombosis, and vascular biology 2007;27(11):2476-83.
2007: S Shahbazi; Peter J Lenting; Caroline Fribourg; Virginie Terraube; Cécile V Denis; Olivier D Christophe
Characterization of the interaction between von Willebrand factor and osteoprotegerin.
Journal of thrombosis and haemostasis : JTH 2007;5(9):1956-62.
2007: Abhay Sagare; Rashid Deane; Robert D Bell; Bradley Johnson; Katie Hamm; Ronan Pendu; Andrew Marky; Peter J Lenting; Zhenhua Wu; Troy Zarcone; Alison Goate; Kevin Mayo; David Perlmutter; Mireia Coma; Zhihui Zhong; Berislav V Zlokovic
Clearance of amyloid-beta by circulating lipoprotein receptors.
Nature medicine 2007;13(9):1029-31.
2007: Janine J J Hulstein; Peter J Lenting; Bas de Laat; R H W M Derksen; Rob Fijnheer; Philip G de Groot
beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation.
Blood 2007;110(5):1483-91.
2007: Quirijn de Mast; Evelyn Groot; Peter J Lenting; Philip G de Groot; Matthew McCall; Robert W Sauerwein; Rob Fijnheer; Andre J A M van der Ven
Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria.
The Journal of infectious diseases 2007;196(4):622-8.
2007: Robert Jan Lebbink; Talitha Eshuis - de Ruiter; Guido J A Kaptijn; Dominique G Bihan; Christine A Jansen; Peter J Lenting; Linde Meyaard
Mouse leukocyte-associated Ig-like receptor-1 (mLAIR-1) functions as an inhibitory collagen-binding receptor on immune cells.
International immunology 2007;19(8):1011-9.
2007: Peter J Lenting; Carina J M van Schooten; Cécile V Denis
Clearance mechanisms of von Willebrand factor and factor VIII.
Journal of thrombosis and haemostasis : JTH 2007;5(7):1353-60.
2007: Peter J Lenting; Cécile V Denis
von Willebrand factor A1 domain: stuck in the middle.
Journal of thrombosis and haemostasis : JTH 2007;5(7):1361-2.
2007: Alexander B Meijer; Jakub Rohlena; Carmen van der Zwaan; Anton-Jan van Zonneveld; Ria C Boertjes; Peter J Lenting; Koen Mertens
Functional duplication of ligand-binding domains within low-density lipoprotein receptor-related protein for interaction with receptor associated protein, alpha2-macroglobulin, factor IXa and factor VIII.
Biochimica et biophysica acta 2007;1774(6):714-22.
2007: Evelyn Groot; Philip G de Groot; Rob Fijnheer; Peter J Lenting
The presence of active von Willebrand factor under various pathological conditions.
Current opinion in hematology 2007;14(3):284-9.
2007: Jovanka Bestebroer; Miriam J J G Poppelier; Laurien H Ulfman; Peter J Lenting; Cécile V Denis; Kok P M van Kessel; Jos van Strijp; Carla J C de Haas
Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil rolling.
Blood 2007;109(7):2936-43.
2007: Carina J M van Schooten; Cécile V Denis; Ton Lisman; J C J Eikenboom; Frank W G Leebeek; Jenny Goudemand; Edith Fressinaud; H Marijke van den Berg; Philip G de Groot; Peter J Lenting
Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels.
Blood 2007;109(6):2430-7.
2007: Peter J Lenting; Philip G de Groot; Simon F De Meyer; Karen Vanhoorelbeke; Cynthia Pruss; David Lillicrap; Isabelle Marx; Cécile V Denis
Correction of the bleeding time in von Willebrand factor (VWF)-deficient mice using murine VWF.
Blood 2007;109(5):2267-8.
2007: Caroline Kamaté; Peter J Lenting; H M van den Berg; T Mutis
Depletion of CD4+/CD25high regulatory T cells may enhance or uncover factor VIII-specific T-cell responses in healthy individuals.
Journal of thrombosis and haemostasis : JTH 2007;5(3):611-3.
2007: Suryasarathi Dasgupta; Yohann Repesse; Jagadeesh Bayry; Ana-Maria Navarrete; Bharath Wootla; Sandrine Delignat; Theano Irinopoulou; Caroline Kamaté; Jean-Marie Saint-Remy; Marc Jacquemin; Peter J Lenting; Annie Borel-Derlon; Srini V Kaveri; Sébastien Lacroix-Desmazes
VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.
Blood 2007;109(2):610-2.
2006: Janine J J Hulstein; Pieter J van Runnard Heimel; Arie Franx; Peter J Lenting; Hein W Bruinse; Karen Silence; Philip G de Groot; Rob Fijnheer
Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome.
Journal of thrombosis and haemostasis : JTH 2006;4(12):2569-75.
2006: Ronan Pendu; Virginie Terraube; Olivier D Christophe; Carl G Gahmberg; Philip G de Groot; Peter J Lenting; Cécile V Denis
P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor.
Blood 2006;108(12):3746-52.
2006: Maghnus O'Seaghdha; Carina J van Schooten; Steven W Kerrigan; jonas emsley; Gregg J Silverman; Dermot Cox; Peter J Lenting; Timothy J Foster
Staphylococcus aureus protein A binding to von Willebrand factor A1 domain is mediated by conserved IgG binding regions.
The FEBS journal 2006;273(21):4831-41.
2006: M T T Pennings; Menno van Lummel; R H W M Derksen; Rolf T Urbanus; Roland A Romijn; Peter J Lenting; Philip G de Groot
Interaction of beta2-glycoprotein I with members of the low density lipoprotein receptor family.
Journal of thrombosis and haemostasis : JTH 2006;4(8):1680-90.
2006: Robert Jan Lebbink; Talitha Eshuis - de Ruiter; Jelle Adelmeijer; Arjan B Brenkman; Joop M van Helvoort; Manuel Koch; Richard W Farndale; Ton Lisman; Arnoud Sonnenberg; Peter J Lenting; Linde Meyaard
Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1.
The Journal of experimental medicine 2006;203(6):1419-25.
2006: Virginie Terraube; Ronan Pendu; Dominique Baruch; Martijn F B G Gebbink; D Meyer; Peter J Lenting; Cécile V Denis
Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice.
Journal of thrombosis and haemostasis : JTH 2006;4(3):519-26.
2006: Hans Ulrichts; Miklós Udvardy; Peter J Lenting; Inge Pareyn; Nele Vandeputte; Karen Vanhoorelbeke; Hans Deckmyn
Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V.
The Journal of biological chemistry 2006;281(8):4699-707.
2005: Janine J J Hulstein; Philip G de Groot; Karen Silence; Agnès Veyradier; Rob Fijnheer; Peter J Lenting
A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B.
Blood 2005;106(9):3035-42.
2005: C J Schooten; Pernilla Tjernberg; Erik Westein; Virginie Terraube; Giancarlo Castaman; J A Mourik; Martine J Hollestelle; Hans L Vos; Rogier M Bertina; H M Berg; J C J Eikenboom; Peter J Lenting; Cécile V Denis
Cysteine-mutations in von Willebrand factor associated with increased clearance.
Journal of thrombosis and haemostasis : JTH 2005;3(10):2228-37.
2005: Cécile V Denis; Sarah J Roberts; Tilman M Hackeng; Peter J Lenting
In vivo clearance of human protein S in a mouse model: influence of C4b-binding protein and the Heerlen polymorphism.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(10):2209-15.
2005: Karin van Dijk; Johanna van der Bom; Peter J Lenting; Philip G de Groot; Eveline P Mauser-Bunschoten; Goris Roosendaal; Diederick Grobbee; H Marijke van den Berg
Factor VIII half-life and clinical phenotype of severe hemophilia A.
Haematologica 2005;90(4):494-8.
2005: Hans Ulrichts; Karen Vanhoorelbeke; Jean-Pierre Girma; Peter J Lenting; Stephan Vauterin; Hans Deckmyn
The von Willebrand factor self-association is modulated by a multiple domain interaction.
Journal of thrombosis and haemostasis : JTH 2005;3(3):552-61.
2005: Patricia P E M Spijkers; Paula da Costa Martins; Erik Westein; Carl G Gahmberg; Jaap-Jan Zwaginga; Peter J Lenting
LDL-receptor-related protein regulates beta2-integrin-mediated leukocyte adhesion.
Blood 2005;105(1):170-7.
2004: Suzanne J A Korporaal; Ingrid A M Relou; Miranda van Eck; Vera Strasser; Martineke Bezemer; Gertie Gorter; Theo Van berkel; Johannes Nimpf; Jan-Willem N Akkerman; Peter J Lenting
Binding of low density lipoprotein to platelet apolipoprotein E receptor 2' results in phosphorylation of p38MAPK.
The Journal of biological chemistry 2004;279(50):52526-34.
2004: Rashid Deane; Zhenhua Wu; Abhay Sagare; Judianne Davis; Shi Du Yan; Katie Hamm; Feng Xu; Margaret Parisi; Barbra LaRue; Hong Wei Hu; Patricia Spijkers; Huang Guo; Xiaomei Song; Peter J Lenting; William E Van Nostrand; Berislav V Zlokovic
LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms.
Neuron 2004;43(3):333-44.
2004: Peter J Lenting; Erik Westein; Virginie Terraube; Anne-Sophie Ribba; Eric G Huizinga; Dominique Meyer; Philip G de Groot; Cécile V Denis
An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation.
The Journal of biological chemistry 2004;279(13):12102-9.
2004: Jeffrey F W Keuren; Dominique Baruch; Paulette Legendre; Cécile V Denis; Peter J Lenting; Jean-Pierre Girma; Theo Lindhout
von Willebrand factor C1C2 domain is involved in platelet adhesion to polymerized fibrin at high shear rate.
Blood 2004;103(5):1741-6.
2004: Philip G de Groot; Menno van Lummel; M T T Pennings; Rolf T Urbanus; H Bas de Laat; Peter J Lenting; R H W M Derksen
Beta2-glycoprotein I and LDL-receptor family members.
Thrombosis research 2004;114(5-6):455-9.
2003: Bianca C H Lutters; R H W M Derksen; Winnie L Tekelenburg; Peter J Lenting; Jef Arnout; Philip G de Groot
Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'.
The Journal of biological chemistry 2003;278(36):33831-8.
2003: Niels Bovenschen; Joachim Herz; Jos M Grimbergen; Peter J Lenting; Louis M Havekes; Koen Mertens; Bart J M van Vlijmen
Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency.
Blood 2003;101(10):3933-9.
2003: Roland A Romijn; Erik Westein; Barend Bouma; Marion E Schiphorst; Jan J Sixma; Peter J Lenting; Eric G Huizinga
Mapping the collagen-binding site in the von Willebrand factor-A3 domain.
The Journal of biological chemistry 2003;278(17):15035-9.
2003: Jakub Rohlena; Joost A Kolkman; Ria C Boertjes; Koen Mertens; Peter J Lenting
Residues Phe342-Asn346 of activated coagulation factor IX contribute to the interaction with low density lipoprotein receptor-related protein.
The Journal of biological chemistry 2003;278(11):9394-401.
2003: Niels Bovenschen; Ria C Boertjes; Gunny Van Stempvoort; Jan Voorberg; Peter J Lenting; Alexander B Meijer; Koen Mertens
Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII.
The Journal of biological chemistry 2003;278(11):9370-7.
2002: Patrick H N Celie; Gunny Van Stempvoort; Caroline Fribourg; Leon J Schurgers; Peter J Lenting; Koen Mertens
The connecting segment between both epidermal growth factor-like domains in blood coagulation factor IX contributes to stimulation by factor VIIIa and its isolated A2 domain.
The Journal of biological chemistry 2002;277(23):20214-20.
2002: Erik Westein; Cécile V Denis; Bonno N Bouma; Peter J Lenting
The alpha -chains of C4b-binding protein mediate complex formation with low density lipoprotein receptor-related protein.
The Journal of biological chemistry 2002;277(4):2511-6.
2001: Olivier D Christophe; Peter J Lenting; Ghislaine Cherel; M Boon-Spijker; Jean-Maurice Lavergne; Ria C Boertjes; Marie-Elisabeth Briquel; A de Goede-Bolder; Jenny Goudemand; S Gaillard; Roseline d'Oiron; Dominique Meyer; Koen Mertens
Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B.
Blood 2001;98(5):1416-23.
2000: JG Neels; BM van den Berg; Koen Mertens; H ter Maat; Hans Pannekoek; Anton-Jan van Zonneveld; Peter J Lenting
Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein.
Blood 2000;96(10):3459-65.
2000: Patrick H N Celie; Peter J Lenting; Koen Mertens
Hydrophobic contact between the two epidermal growth factor-like domains of blood coagulation factor IX contributes to enzymatic activity.
The Journal of biological chemistry 2000;275(1):229-34.
2000: JG Neels; Niels Bovenschen; Anton-Jan van Zonneveld; Peter J Lenting
Interaction between factor VIII and LDL receptor-related protein. Modulation of coagulation?
Trends in cardiovascular medicine 2000;10(1):8-14.
1999: Joost A Kolkman; Olivier D Christophe; Peter J Lenting; Koen Mertens
Surface loop 199-204 in blood coagulation factor IX is a cofactor-dependent site involved in macromolecular substrate interaction.
The Journal of biological chemistry 1999;274(41):29087-93.
1999: Peter J Lenting; JG Neels; BM van den Berg; P P Clijsters; D W Meijerman; Hans Pannekoek; Jan A van Mourik; Koen Mertens; Anton-Jan van Zonneveld
The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein.
The Journal of biological chemistry 1999;274(34):23734-9.
1999: Koen Mertens; Patrick H N Celie; Joost A Kolkman; Peter J Lenting
Factor VIII-factor IX interactions: molecular sites involved in enzyme-cofactor complex assembly.
Thrombosis and haemostasis 1999;82(2):209-17.
1999: Joost A Kolkman; Peter J Lenting; Koen Mertens
Regions 301-303 and 333-339 in the catalytic domain of blood coagulation factor IX are factor VIII-interactive sites involved in stimulation of enzyme activity.
The Biochemical journal 1999;339 ( Pt 2)():217-21.
1998: Peter J Lenting; Jan A van Mourik; Koen Mertens
The life cycle of coagulation factor VIII in view of its structure and function.
Blood 1998;92(11):3983-96.
1998: Olivier D Christophe; Peter J Lenting; Joost A Kolkman; G G Brownlee; Koen Mertens
Blood coagulation factor IX residues Glu78 and Arg94 provide a link between both epidermal growth factor-like domains that is crucial in the interaction with factor VIII light chain.
The Journal of biological chemistry 1998;273(1):222-7.
1996: Peter J Lenting; Olivier D Christophe; H Maat; D J Rees; Koen Mertens
Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding.
The Journal of biological chemistry 1996;271(41):25332-7.
1996: M J Donath; Peter J Lenting; Jan A van Mourik; Koen Mertens
Kinetics of factor VIII light-chain cleavage by thrombin and factor Xa. A regulatory role of the factor VIII heavy-chain region Lys713-Arg740.
European journal of biochemistry / FEBS 1996;240(2):365-72.
1996: Peter J Lenting; J W van de Loo; M J Donath; Jan A van Mourik; Koen Mertens
The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX.
The Journal of biological chemistry 1996;271(4):1935-40.
1995: M J Donath; R T de Laaf; P T Biessels; Peter J Lenting; J W van de Loo; Jan A van Mourik; Jan Voorberg; Koen Mertens
Characterization of des-(741-1668)-factor VIII, a single-chain factor VIII variant with a fusion site susceptible to proteolysis by thrombin and factor Xa.
The Biochemical journal 1995;312 ( Pt 1)():49-55.
1995: Peter J Lenting; H ter Maat; P P Clijsters; M J Donath; Jan A van Mourik; Koen Mertens
Cleavage at arginine 145 in human blood coagulation factor IX converts the zymogen into a factor VIII binding enzyme.
The Journal of biological chemistry 1995;270(25):14884-90.
1995: M S Donath; Peter J Lenting; Jan A van Mourik; Koen Mertens
The role of cleavage of the light chain at positions Arg1689 or Arg1721 in subunit interaction and activation of human blood coagulation factor VIII.
The Journal of biological chemistry 1995;270(8):3648-55.
1994: Peter J Lenting; M J Donath; Jan A van Mourik; Koen Mertens
Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII.
The Journal of biological chemistry 1994;269(10):7150-5.